Domestic listing status and sales channel description of Tirpotide/Tirzepatide

In recent years, with the rapid growth in demand for weight loss and sugar control, Tirzepatide/Tirzepatide (Tirzepatide) has continued to receive increasing attention in China. During 2024–2025 , the drug was approved for marketing in China and has been officially sold through some provincial and municipal hospitals and Internet medical platforms. As a GIP/GLP-1 dual receptor agonist, Tirzepatide ’s real clinical performance in reducing weight and improving blood sugar is highly anticipated. Therefore, the launch news often becomes a hot topic in health, and also attracts a large number of patients to inquire about purchasing channels and usage procedures.

Currently, tilsiparatide has been officially launched in China. It is an original drug and has been included in the national medical insurance catalog. According to public market information, the price of original drugs sold in China is about three to four thousand yuan due to differences in specifications, distribution channels and supply conditions. Among overseas versions, the price of Japanese original drugs is relatively low, about more than a thousand yuan. However, due to cross-border transportation, regulatory requirements and purchase compliance issues, patients are not recommended to obtain them through informal purchasing channels to avoid the risk of encountering counterfeit drugs or improper storage leading to reduced efficacy.

In terms of sales channels, the country mainly obtains it through three formal channels : one is the endocrinology department or obesity management clinic of a large tertiary hospital, which can be purchased directly at the hospital pharmacy after the doctor issues a prescription; the other is an Internet hospital platform with prescription review qualifications, which obtains prescriptions through online consultation and then distributes them through the cold chain of the partner pharmacy; the third is some pharmaceutical e-commerce platforms that meet the requirements, but still need to upload prescriptions for review. These formal channels all have cold chain storage and transportation conditions, which can ensure the stability of drugs during transportation.

For patients who plan to use tisiparatide, it is recommended to give priority to hospital prescription channels and have professional doctors evaluate the indications, dosage and possible adverse reactions. In addition, be wary of advertisements such as "Buy Without Prescription" and "Cheap Overseas Purchasing Agency" on the market to avoid buying products without batch numbers and from unknown sources. Generally speaking, tilsiparatide is already available in China, so it should be used scientifically under the guidance of doctors, and drug quality and therapeutic effects should be ensured through formal channels.

Reference materials:https://www.ncbi.nlm.nih.gov/books/NBK585056/